A Study of LY2523355 in Patients With Solid Cancer

A Phase 1 Study of LY2523355 in Patients With Solid Cancer

The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer. The secondary objectives are to study the pharmacokinetics and antitumor effect.

Inclusion Criteria:

• Histological and/or cytological evidence of solid tumors
• A diagnosis of advanced and/or metastatic solid tumors
• Patients who are refractory to standard therapy or for which no proven effective therapy exists
• Written informed consent
• Appropriate bone marrow, hepatic and renal functions
• ECOG PS =< 1

Exclusion Criteria:

• Have serious preexisting complication
• Have active infection which requires intravenous antibiotics
• Have symptomatic central nervous system metastases
• Have current acute or chronic leukemia
• Have had an autologous or allogenic hematopoietic stem cell transplantation
• Have active multiple cancers